News
News

The latest updates from AFAR.

Board member in the News: James Kirkland’s research on screening platform for senolytics in Nature

Sep 18
2017

Board member in the News: James Kirkland’s research on screening platform for senolytics in Nature View MoreBACK

On September 4, 2017, Nature Communications published research co-authored by 2012 Glenn/AFAR BIG Award winner and AFAR Board President-Elect James L. Kirkland, MD, PhD, on the use of a screening platform to identify more senolytic drugs.

https://www.nature.com/articles/s41467-017-00314-z

As reported in “Identification of HSP90 inhibitors as a novel class of senolytics,” Kirkland and his co-authors “established a senescence associated β-galactosidase assay as a screening platform to rapidly identify drugs that specifically affect senescent cells”…”to identify novel and more optimal senotherapeutic drugs and combinations.”

Senolytic or senotherapeutic drugs target increased senescent cell burden in various tissues, a major contributor to aging and age-related diseases.

The study concludes:

“Indeed, our preliminary results using the screening platform suggests that it may be possible to identify more effective senolytic drug combinations, including combinations of other drugs with HSP90 inhibitors, which could be used to extend healthspan in humans. Senolytic drugs also might prove useful in delaying, preventing, or treating age-related chronic diseases as well as other diseases and conditions related to increased senescent cell burden, such as idiopathic pulmonary fibrosis, obesity with metabolic syndrome, osteoarthritis, and cancer survivors treated with irradiation or chemotherapy.”

Read the full article here:
 

James L. Kirkland, MD, PhD, is is the Director of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic.


For more on cellular senescence, visit AFAR’s expert-edited Infoaging Guide to Celluar Senescence here.
 





View MoreBACK TO TOP